396 A Phase I, Dose-finding Study of BI 853520, a Potent and Selective Inhibitor of Protein Tyrosine Kinase 2 in Patients with Advanced or Metastatic Solid Tumors by de Jonge, M, Sahebjam, S, Mathijssen, R.H, Razak, A, van der Biessen, D, Pronk, L.C, Schnell, D, Siu, L.L

Get full text

579 Phase I and Pharmacokinetic (PK) Study of Pazopanib in Combination with Two Schedules of Docetaxel (D) in Patients (pts) with Advanced Solid Tumors by Hamberg, P, Mathijssen, R.H, de Bruijn, P, van der Biessen, D, Loos, W.J, Sleijfer, S, Verweij, J, de Jonge, M.J

Get full text

245 Towards Prediction of Efficacy of Chemotherapy: a Proof of Concept Study in Lung Cancer Patients Using [11C]docetaxel and Positron Emission Tomography by van der Veldt, A.A, Lubberink, M, Mathijssen, R.H, Loos, W.J, Eriksson, J, Windhorst, A.D, Hendrikse, N.H, Postmus, P.E, Smit, E.F, Lammertsma, A.A

Get full text

424 Taxane Efficacy is Positively Related to Intratumoral Concentrations in Patient-derived Prostate Cancer Xenografts by de Morrée, E.S, de Ridder, C.M, de Bruijn, P, Burger, H, Wiemer, E.A.C, Mathijssen, R.H, de Wit, R, van Weerden, W.M

Get full text

420 Increased Clearance of Docetaxel in Androgen Deprived Prostate Cancer Patients by Nieuweboer, A.J.M, de Graan, A.J, de Jonge, M.J.A, de Bruijn, P, Friberg, L.E, van Doorn, L, Wiemer, E.A.C, de Wit, R, Mathijssen, R.H

Get full text

654 Predictive value of a dextromethorphan phenotyping test for endoxifen exposure by de Graan, A.J, Teunissen, S.F, de Vos, F.Y, Loos, W.J, van Schaik, R.H, de Jongh, F.E, Seynaeve, C, Verweij, J, Beijnen, J.H, Mathijssen, R.H

Get full text

19P Effects of CTLA-4 single nucleotide polymorphisms (SNPs) on toxicity of ipilimumab-containing regimens in patients with advanced stage melanoma by Joode, K.D., Rojas Mora, A., Van Schaik, R., Zippelius, A., Van der Veldt, A.A.M., Gerard, C.L., Läubli, H., Michielin, O.A., von Moos, R.A.F., Joerger, M., Levesque, M.P., Aeppli, S., Mangana, J., Mangas, C., Meyer, S., Leoni-Parvex, S., Mathijssen, R.H., Metaxas, Y.

Get full text

31P The IOpener study: Tyrosine kinase activity profiling to predict response to immune checkpoint inhibitors in patients with advanced stage non-small cell lung cancer by Joode, K.D., Groen, H.J.M., van den Heuvel, M., Kloover, J.S., van der Meer, F., Stigt, J.A., van der Leest, C.H., Van Den Borne, B., de Wijn, R., Hurkmans, D.P., van den Heuvel, D.M.A., van Doorn, T., Pinedo, B., Kapiteijn, E., Debets, R., Verdegaal, E., van der Burg, S.H., Groten, J.P., Aerts, J.G., Mathijssen, R.H.

Get full text

Between unity and disparity: current treatment protocols for common orofacial clefts in European expert centres by van Roey, V L, Mink van der Molen, A B, Mathijssen, I M J, Akota, I, de Blacam, C, Breugem, C C, Craveiro Matos, E M, Dávidovics, K, Dissaux, C, Dowgierd, K, Eberlinc, A, Hakelius, M, Heliövaara, A, Hens, G Z, Khonsari, R H, Krimmel, M, Lux, S, Mark, H, Mazzoleni, F, Meazzini, M C, Munill Ferrer, M, Nienhuijs, M E, Peterson, P, Piacentile, K, Rubio Palau, J, Sylvester-Jensen, H C, Zafra Vallejo, V, Versnel, S L

Get full text